Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Mycosis Fungoides 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Waldenstrom Macroglobulinemia 1Neoplasms 1Neoplasm Metastasis 1Mycoses 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

Rituximab 41Cyclophosphamide 23Peripheral Blood Stem Cell Transplantation 15Lenalidomide 14ibrutinib 11fludarabine phosphate 11Etoposide 10Bortezomib 10Filgrastim 9Bendamustine Hydrochloride 9Mycophenolic Acid 8Melphalan 8Cytarabine 8venetoclax 7fludarabine 7Whole-Body Irradiation 7Vincristine 7Cyclosporine 7CT-P10 7Methotrexate 6obinutuzumab 5acalabrutinib 5Doxorubicin 5Carmustine 5Carboplatin 5Biopsy 5pembrolizumab 4ibritumomab tiuxetan 4carmustine, poliferprosan 20 drug combination 4Tacrolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Mantle-Cell × ProMune × Clear all
NCT00438880 2016-02-04

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Mayo Clinic

Phase 1/2 Completed
38 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡